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Abstract
Candida auris is an emerging, multidrug-resistant yeast that can spread in healthcare settings. It 
can cause invasive infections with high mortality and is difficult to identify using traditional yeast 
identification methods. C. auris has been reported in over a dozen countries, and as of July 2017, 
99 clinical cases have been reported in the United States;. C. auris can colonize skin and persist in 
the healthcare environment, allowing for transmission between patients. Prompt investigation and 
aggressive interventions, including notification of public health agencies, implementation of 
contact precautions, thorough environmental cleaning and disinfection, infection control 
assessments, contact tracing and screening contacts to assess for colonization, and retrospective 
review of microbiology records and prospective surveillance for cases at laboratories are all 
needed to limit the spread of C. auris. This review summarizes the current recommended approach 
to manage cases of C. auris and control transmission of C. auris in healthcare facilities.
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Background
Candida auris is an emerging, multidrug-resistant yeast that can cause invasive infections, 
and has been associated with outbreaks in healthcare settings. C. auris was first described in 
2009 after isolation from external ear discharge from a patient in Japan [1]. Reports of 
bloodstream infections followed quickly thereafter from South Korea and India, in which 
persistent infection despite treatment and drug resistance to fluconazole and amphotericin B 
were described [2–7]. Subsequently, C. auris infections have been reported in over a dozen 
countries [8–13] (Figure). Although attributable mortality is unknown, 30–60% of patients 
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with C. auris infection have died [8]. In some places, C. auris now accounts for an increasing 
proportion of candidemia cases; an unknown pathogen before 2009, C. auris caused 4–8% of 
candidemia in Indian intensive care units (ICUs) during 2011–2012 and 38% of candidemia 
in one Kenyan hospital during 2010–2013 [11, 14]. Whole-genome sequencing of C. auris 
isolates has revealed four distinct clades that cluster geographically (South Asia, East Asia, 
South Africa, and South America) with a high degree of relatedness within clades, 
suggesting independent emergence with transmission within a geographic area rather than a 
single emergence and spread [8].
In April 2015, a specialty hospital in the United Kingdom (U.K.) identified a C. auris 
outbreak among patients in a cardiothoracic intensive care unit. [15]. Testing revealed 
colonization of additional patients and C. auris on hospital surfaces and equipment. Control 
of the outbreak required implementation of aggressive infection control practices, including 
use of contact precautions and thrice-daily room disinfection with bleach. Although 
outbreaks of Candida parapsilosis have been reported, Candida infections are usually 
thought to result from autoinfection with host flora rather than transmission from external 
sources [16, 17]. The U.K. outbreak clearly demonstrated that C. auris can be transmitted in 
healthcare settings [18].
In response to global reports and the U.K. hospital outbreak, the Centers for Disease Control 
and Prevention (CDC) issued a clinical alert to U.S. healthcare facilities about C. auris in 
June 2016 [19]. As of July 14, 2017, 209 patients (99 from clinical cultures, 110 screened 
contacts) were reported to have C. auris infection or colonization [20]. All but one of these 
cases occurred in 2015 or later, suggesting that this organism has emerged only recently in 
the U.S. Nearly all cases have occurred within limited geographic areas. Given the recent 
emergence and geographic concentration of cases, an opportunity exists to control the spread 
of this organism before it becomes more widespread.
Experience with other multidrug-resistant organisms (MDROs) suggests that an early, 
aggressive approach to control the organism when newly emerging is more effective and 
efficient in controlling transmission than responding when more widespread [21,22]. This 
review summarizes the current recommended approach to managing cases of C. auris and 
control transmission of C. auris in healthcare facilities. This effort requires coordination 
between all involved stakeholders, including healthcare facilities, clinicians, public health 
practitioners, and industry. Many of the principles for containment of C. auris are similar to 
those for other MDROs.
C. auris identification
The first step in controlling C. auris is identification. C. auris can be misidentified when 
using traditional biochemical methods [23]. Depending on the identification method used 
(e.g., VITEK-2, API-20C, BD-Phoenix, Microscan), C. auris should be suspected when an 
isolate is identified as certain Candida species, such as Candida haemulonii, Candida famata, 
Candida sake, Candida catenulata, or Rhodotorula glutinis, or if species identification cannot 
be obtained [23]. Currently, accurate identification for C. auris can be performed by Vitek 
MS and Bruker Biotyper brand MALDI-TOF using research use only databases. Molecular 
methods based on sequencing of the D1–D2 region of the 28s rDNA or internal transcribed 
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spacer (ITS) region can also reliably identify C. auris [12, 24–26]. Clinicians should be 
aware of the diagnostic instruments used in their hospital laboratories and their ability to 
detect C. auris [27]. Clinical laboratories can request testing of suspect C. auris isolates from 
their state or regional public health laboratory or CDC. Laboratories should also consider 
reviewing historical microbiology records for suspect isolates (e.g., C. haemulonii) to 
identify missed cases of C. auris.
Antifungal resistance
Antifungal susceptibility testing (AFST) for all clinically-relevant Candida isolates is 
recommended in the 2016 Infectious Diseases Society of America (IDSA) Clinical Practice 
Guidelines for Candidiasis [18]. Resistance to ≥1 antifungal drugs in an isolate with 
ambiguous identification should raise the suspicion of C. auris and prompt further testing. In 
one collection of 54 C. auris isolates from five countries, 93% were resistant to fluconazole, 
35% to amphotericin B, and 7% to echinocandins. In total, 41% were resistant to ≥2 
antifungal classes [8]. In the U.S., 86% of the first 35 cases were resistant to fluconazole, 
43% to amphotericin B, and 1 (3%) to echinocandins [20]. Although minimum inhibitory 
concentration (MIC) breakpoints have not been established for C. auris, breakpoints are 
suggested based on those used for closely-related Candida species and expert opinion, 
especially for amphotericin B, for which no breakpoints exist for any Candida species [28]. 
Tentative MIC breakpoints (in µg/mL) for resistance include ≥32 fluconazole, ≥2 
amphotericin B, ≥2 caspofungin, and ≥4 for anidulafungin and micafungin.
Treatment of C. auris infection
Consultation with an infectious disease specialist is highly recommended. Despite its 
multidrug resistant nature, most C. auris isolates to date have been susceptible to 
echinocandins. The recommended initial therapy for clinically relevant infections with C. 
auris in adults is an echinocandin at standard dosing. Patients should be monitored closely 
for resolution of infection given that resistance to echinocandins has been documented and 
because resistance has emerged on serial isolates from a single patient after exposure to the 
drug. Switching to, or adding, liposomal amphotericin B (5 mg/kg daily) could be 
considered if the patient is clinically unresponsive to echinocandin treatment or has 
fungemia for >5 days. Other management considerations for C. auris are similar to Candida 
infections with other species; practitioners should refer to the 2016 IDSA Clinical Practice 
Guidelines [18].
Controlling C. auris Transmission in Healthcare Settings
The presence of a single case in a healthcare facility should prompt an aggressive response 
and investigation because C. auris can cause healthcare-associated outbreaks. Patients can 
remain colonized on their skin and other body sites indefinitely after resolution of invasive 
infections, allowing C. auris to be shed into the healthcare environment, where it persists on 
surfaces and can be transmitted to other patients [15, 29]. Containment efforts should focus 
on identifying patients who are infected or colonized with C. auris and implementing 
infection control interventions, including hand hygiene, contact precautions, and thorough 
environmental cleaning and disinfection [28].
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Response to a case of C. auris
As soon as C. auris is suspected, the patient should be placed in a single room under contact 
precautions until definitive identification is available. When C. auris is confirmed at a 
healthcare facility, the following actions should be taken:
Notify—A case of C. auris should be reported as soon as possible to the state or local health 
department and CDC. CDC has established an email address for reporting: 
candidaauris@cdc.gov.
Institute infection control measures—Standard and contact precautions with 
placement of the patient in a single room is recommended. Adherence to proper hand 
hygiene with alcohol-based hand rub or soap and water should be reinforced [30].
C. auris can persist on surfaces in the healthcare settings [31]. Thorough daily and terminal 
cleaning of the patient’s room and any mobile equipment used should be performed with an 
Environmental Protection Agency (EPA)-registered hospital-grade disinfectant effective 
against Clostridium difficile spores [32]. Preliminary laboratory testing suggests that certain 
commonly-used hospital disinfectants, notably quaternary ammonia compounds, are not 
sufficiently effective against C. auris.
Perform detailed case review—Basic information about the case-patient, including 
demographic characteristics and clinical history should be obtained. In the United States, 
patients with C. auris were found to have had on average three healthcare facility encounters 
in the 90 days preceding their diagnosis; the majority had been admitted to a high acuity 
LTCF. It is important to obtain records of recent healthcare encounters, including stays at 
other acute care hospitals and LTCFs in order to assess for possible transmission at the other 
facilities.
Taking a detailed travel history, especially receipt of healthcare in countries where C. auris 
cases have been reported, is important. Several U.S. case-patients have had a recent history 
of hospitalization in countries with a large burden of C. auris, including India, Pakistan, 
South Africa, and Venezuela. Based on whole-genome sequencing at CDC, most isolates 
from U.S. patients are closely related to isolates from South Asia and South America.
Identify colonized patients through contact investigation—Contact investigation 
should be conducted to identify persons who were exposed to an incident case to detect 
transmission. As part of a detailed C. auris case review, it is important to identify 
epidemiologically-linked patients for possible screening, as colonized patients pose a risk 
for transmission. Current or past roommates are considered at high risk for becoming 
colonized and should be screened even if they are no longer admitted to the facility. Other 
potential contacts might include patients who overlapped on a ward with a patient with C. 
auris and patients who moved into a room recently vacated by a patient with C. auris, 
especially if cleaning practices were suboptimal.
To identify colonized people, one or more high-yield body sites should be sampled with a 
swab. For example, studies evaluating screening for methicillin-resistant Staphylococcus 
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aureus (MRSA) have shown nares to be the highest yield site, ranging from 71–84% [33–
35]. Yield can be increased further if additional body sites are included; for example, MRSA 
detection is >90% if nares, throat, and perineum are all sampled [35]. Because no studies on 
sampling sites exist for C. auris, early cases were sampled from multiple body sites 
(including nares, ears, oropharynx, axilla, groin, and rectum) to determine those with highest 
yield. Approximately 90% of cases were positive by axilla or groin swab. Nares was the 
second most commonly positive body site. Screening of epidemiologically-linked patients 
with a composite swab of the bilateral axillae and groin is recommended; additional body 
sites, including nares, may be sampled if feasible. Unlike screening for MRSA or CRE, 
laboratory processing of swabs taken to identify C. auris colonization is not currently 
commercially available and should be coordinated through local or state health departments 
and CDC. All patients identified as colonized with C. auris should be managed in the same 
manner as the index patient and placed in single room on contact precautions. It is also 
important to ensure that the patient’s status and required infection control measures are 
communicated at the time of transfer to another healthcare facility.
No known decolonization methods have been established. C. auris is susceptible to 
chlorhexidine in vitro and has been used in certain settings for source control; however, 
despite daily chlorhexidine bathing, patients described in the U.K. continued to be colonized 
with C. auris [15]. Further study is needed on efficacy of chlorhexidine and other products 
for decolonization before recommendations for their use can be made.
Review of microbiology records—Because C. auris is commonly misidentified as other 
Candida species, clinical laboratories serving the affected facility should review 
microbiology records to identify other suspected cases, as should clinical laboratories 
serving other facilities where the patient recently received care. These reviews should 
include specimens from all body sites and include ≥1 year of microbiology records, 
preferably as far back as 2015. Laboratories that have identified a case of C. auris should be 
on heightened alert for additional cases of C. auris.
Response to more than one case of C. auris
Although a case of C. auris is enough to prompt an investigation, >1 case raises the concern 
for transmission. When >1 patient with C. auris is identified at a healthcare facility, 
including patients identified through screening, additional actions are recommended.
Perform infection control assessments—Infection control assessments should be 
conducted to look for opportunities for improvement. These assessments offer an 
opportunity to collaborate with staff and provide comprehensive education that benefits the 
facility beyond the control of C. auris. Particular areas to target during these assessments 
include hand hygiene, contact precautions, and environmental cleaning and disinfection.
Hand hygiene assessment should include evaluating the availability of appropriate resources, 
like alcohol-based hand rub and ready access to sinks with soap and water. Use monitoring 
programs to ensure staff adherence and to target ongoing education and encouragement. 
When evaluating the implementation of contact precautions, assess the availability of 
personal protective equipment (PPE), clear signage outside patient rooms, and staff 
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adherence. In resource-limited settings, facilities may have to consider cohorting patients 
with C. auris together; however, if patients have multiple MDROs, care should be taken not 
to cohort patients with different MDROs together.
In the U.K. outbreak, t horough cleaning and disinfection with sodium hypochlorite-based 
products and hydrogen peroxide vapor was reported to be a key factor in eventual control of 
the outbreak [15]. Environmental cleaning and disinfection in healthcare facilities should be 
a collaborative effort between environmental services, patient support staff, and healthcare 
workers. Training on use of the proper agent, mixed to the proper concentration (if required), 
and appropriate contact time are essential to ensuring surfaces are adequately disinfected. 
Samples from C. auris patient rooms in the after terminal cleaning with sodium 
hypochlorite-based products have not yielded growth of C. auris. If these measures fail to 
stop transmission, closure of an affected ward for a certain period may be needed to interrupt 
transmission [15].
Perform additional case finding—Broader patient screening should be strongly 
considered in facilities with >1 patient with C. auris, especially in high-acuity nursing 
homes, where substantial transmission of C. auris has occurred. Point-prevalence surveys 
(PPS) for C. auris colonization of affected units or an entire facility can rapidly assess the 
extent of transmission and identify patients who may be sources of ongoing transmission.
Results from the initial PPS can help determine need for further screening. For example, if 
multiple patients on a particular ward are colonized, the next step might be to screen the 
entire floor or facility. In general, if further transmission is detected on PPS, additional PPS 
are warranted after interventions are undertaken to assess the impact of these interventions 
on transmission.
Consider environmental or healthcare worker sampling in limited settings—
Early U.S. investigations of C. auris included environmental sampling of surfaces in case-
patients’ hospital rooms during active infection, and many different types of surfaces yielded 
positive cultures for C. auris. Based on these results, contamination of affected patients’ 
rooms is expected, and environmental sampling is generally not recommended. However, 
environmental sampling could be considered if epidemiologic evidence links specific 
environmental sources to C. auris transmission or in situations where ongoing transmission 
is identified despite adherence to recommended interventions.
Whereas transient contamination of hands of healthcare personnel (HCP) is likely to play a 
role in C. auris transmission, the role of chronic HCP colonization is unclear. Systematic 
sampling of the hands, nose, axilla, groin, and throat of 258 HCP was conducted as part of 
the U.K. investigation and identified a single HCP with a positive nares swab who later 
tested negative from the same site, suggesting transient carriage [15]. Screening of HCP 
should be considered only if an epidemiologic investigation suggests HCPs as a likely 
source or in situations where ongoing transmission is identified despite adherence to 
recommended interventions.
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Consider regional notification to laboratories and other healthcare facilities—
When ≥1 C. auris case is identified, local or state health departments may consider notifying 
laboratories and healthcare facilities in the region to raise awareness and aid in additional 
case-finding. Laboratory messaging from public health agencies should include information 
about when to suspect and how to identify C. auris and highlight the importance of 
determining Candida species and AFST [18]. Microbiology record reviews can also be 
requested on a wider scale at other facilities in the region to identify other suspect cases. 
These laboratories should also be encouraged to conduct prospective surveillance for new 
cases. Because other Candida species do not typically cause outbreaks, heightened infection 
control practices are not typically recommended in the control of Candida infections. 
Therefore, it is particularly important to educate HCPs in the region about the distinct ability 
of C. auris to spread in healthcare settings and about current control recommendations to 
improve identification, notification, and implementation of infection control measures.
Unanswered Questions and Ongoing Work
Even as more becomes known about C. auris, many unanswered questions remain that 
directly affect the implications of testing and identifying cases. These questions include:
1. Where did C. auris come from and why is it emerging now?
2. What should salvage treatment consist of in cases where the organism is resistant 
to the three main classes of antifungals?
3. How can C. auris colonization be rapidly detected?
4. How long can a person remain colonized with C. auris?
5. What methods are effective for reducing the burden of C. auris colonization?
6. What are risk factors for infection in a patient colonized with C. auris?
7. How effective are the recommended infection control strategies at containing C. 
auris?
8. What is the prevalence is C. auris in the community and does transmission occur 
there?
9. How rapidly and under what circumstances does C. auris become resistant to 
antifungal drugs?
Future studies will aim to answer these questions in addition to others in order to better 
understand C. auris and how best to contain its spread.
Conclusion
Candida auris is a newly emerging, often multidrug-resistant fungal pathogen, similar in 
many ways to bacterial MDROs with which hospital epidemiologists and clinicians are 
already familiar. The ability of Candida auris to colonize the skin, persist in the healthcare 
environment, and cause healthcare-associated outbreaks has changed the way we think about 
Candida infections. Prevention and containment of C. auris requires many of the same 
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interventions that are used to contain other MDROs that spread in healthcare settings, and it 
critical that these interventions are implemented early and thoroughly.
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Summary
Candida auris is an emerging multidrug-resistant yeast that can spread in healthcare 
settings. This review summarizes the current recommended approach to manage cases of 
C. auris and control transmission of C. auris in healthcare facilities.
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Box 1
CANDIDA AURIS IS CONCERNING BECAUSE OF THE FOLLOWING 
REASONS
It can cause invasive infections with high mortality
59% all-cause mortality in early studies
Majority of cases in the United States to date have been bloodstream 
infections (candidemia)
It is difficult to identify.
Most often misidentified as Candida haemulonii by conventional biochemical 
methods
MALDI-TOF or DNA sequencing are required to identify C. auris
It is often multidrug resistant.
Most isolates are resistant to fluconazole
Some are resistant to amphotericin B
Small proportion are resistant to echinocandins
Resistance to all 3 classes of antifungals has been observed in other world 
regions
It can spread in healthcare settings.
Persists on patients’ skin and the healthcare environment, allowing for 
transmission to occur between patients in healthcare facilities
Outbreaks of C. auris have been reported in several countries
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Box 2
INTERVENTIONS NEEDED FOR A CASE OF CANDIDA AURIS
Notify public health agency of confirmed or suspected C. auris cases
Report to the Centers for Disease Control and Prevention at 
candidaauris@cdc.gov
Place patient in a single room if possible and institute standard and contact 
precautions
Reinforce and enhance hand hygiene practices
Institute thorough environmental cleaning and disinfection of the patient care area
Use an Environmental Protection Agency-registered disinfectant active 
against Clostridium difficile for routine and terminal disinfection
Implement contact tracing and testing to identify other patients colonized with C. 
auris
Composite swab of axilla and groin to assess for skin colonization
Swab roommates and those with longest overlapping contact with the case 
patient
Conduct microbiology records review
Review past microbiology records (at least for the preceding 1 year ) for 
suspect or confirmed cases of C. auris at the institution.
Set up enhanced surveillance for C. auris in the laboratory serving the 
healthcare facility to detect any future cases of C. auris immediately
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Figure 1. 
Countries from which Candida auris has been reported, as of July 2017. Canada, Germany, 
Japan, Norway, and Kuwait have each reported a single case of C. auris. Larger numbers of 
cases have been reported in Colombia, India, Israel, Kenya, Oman, Pakistan, Panama, South 
Korea, Spain, South Africa, the United Kingdom, and Venezuela. Current case counts of C. 
auris for all countries are not available. United States case counts are available on the 
Centers for Disease Control and Prevention website. Most US cases are concentrated in the 
New York City and New Jersey area, though at least 7 other states have reported cases as of 
August 2017.
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